Successful treatment of life-threatening melioidosis with activated protein C and meropenem

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 1, 2007, Pages 83-87

  Tan, Che Kim ^a   Chan, Khee Siang ^a   Yu, Wen Liang ^a   Chen, Chin Ming ^a   Cheng, Kuo Chen ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Burkholderia pseudomallei; Melioidosis; Pneumonia; Recombinant proteins; Respiratory distress syndrome, adult; Shock, septic; Thienamycins

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CORTICOSTEROID; DOPAMINE; DROTRECOGIN; HEMOGLOBIN A1C; INOTROPIC AGENT; LACTIC ACID; MEROPENEM; MINOCYCLINE; ANTIINFECTIVE AGENT; FIBRINOLYTIC AGENT; PROTEIN C; RECOMBINANT PROTEIN; THIENAMYCIN DERIVATIVE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BURKHOLDERIA PSEUDOMALLEI; CASE REPORT; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; ENDOTRACHEAL INTUBATION; FLUID RESUSCITATION; GLYCEMIC CONTROL; HEART RATE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LABORATORY TEST; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MELIOIDOSIS; METABOLIC ACIDOSIS; MORTALITY; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMONIA; SEPTIC SHOCK; THORAX RADIOGRAPHY; TREATMENT OUTCOME; BACTERIAL PNEUMONIA; DRUG COMBINATION; MIDDLE AGED;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MALE; MELIOIDOSIS; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PNEUMONIA, BACTERIAL; PROTEIN C; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK, SEPTIC; THIENAMYCINS;

EID: 34347379780     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. White NJ. Melioidosis. Lancet. 2003;361:1715-22.
2. Currie BJ, Jacups SP. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis. 2003;9:1538-42.
3. Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, Selva-Nayagam S, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis. 2000;31:981-6.
4. Leelarasamee A. Recent development in melioidosis. Curr Opin Infect Dis. 2004;17:131-6.
5. Hsueh PR, Teng LJ, Lee LN, Yu CJ, Yang PC, Ho SW, et al. Melioidosis: an emerging infection in Taiwan? Emerg Infect Dis. 2001;7:428-33.
6. Taiwan Center for Disease Control. Melioidosis. Available from: http://www.cdc.gov.tw/index_info_info.asp?data_id= 1373
7. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-73.
8. Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother. 2004;48:1763-5.
9. Inglis TJ, Rodrigues F, Rigby P, Norton R, Currie BJ. Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods. Antimicrob Agents Chemother. 2004;48:2999-3005.
10. Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, Rajanuwong A, Wuthiekanun V. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis. 1999;29:381-7.
11. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest. 2001;120:1072-7.
12. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C; Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405-33.
13. Cheng AC, Jacups SP, Gal D, Mayo M, Currie BJ. Extreme weather events and environmental contamination are associated with case-clusters of melioidosis in the Northern Territory of Australia. Int J Epidemiol. 2006;35:323-9.
14. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
15. LaRosa S, Opal S, Utterback B, Yan B, Helterbrand J, Simpson A, et al. Evidence of coagulation activation in patients with acute septicemic melioidosis. Presented at the 20th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium; 2000.
16. Chan KP, Low JG, Raghuram J, Fook-Chong SM, Kurup A. Clinical characteristics and outcome of severe melioidosis requiring intensive care. Chest. 2005;128:3674-8.
17. Athan E, Allworth AM, Engler C, Bastian I, Cheng AC. Melioidosis in tsunami survivors. Emerg Infect Dis. 2005;11: 1638-9.
18. Kongsaengdao S, Bunnag S, Siriwiwattnakul N. Treatment of survivors after the tsunami. N Engl J Med. 2005;352:2654-5.